B4GALNT3 | Beta-1,4-N-acetyl-galactosaminyl transferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
ERC1 | ELKS/RAB6-interacting/CAST family member 1 | Cancer-related genes Disease related genes
| | | | | Expressed in all |
CACNA1C | Calcium channel, voltage-dependent, L type, alpha 1C subunit | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
FKBP4 | FK506 binding protein 4, 59kDa | Enzymes Plasma proteins
| | | | | Expressed in all |
NRIP2 | Nuclear receptor interacting protein 2 | | | | | | Mixed |
FOXM1 | Forkhead box M1 | Cancer-related genes Transcription factors
| | | | | Mixed |
TSPAN9 | Tetraspanin 9 | Predicted membrane proteins
| | | | | Tissue enhanced |
EFCAB4B | EF-hand calcium binding domain 4B | | | | | | Tissue enhanced |
AKAP3 | A kinase (PRKA) anchor protein 3 | | | | | | Tissue enriched |
NDUFA9 | NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa | Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
VWF | Von Willebrand factor | Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Mixed |
CD9 | CD9 molecule | Cancer-related genes CD markers Plasma proteins Predicted membrane proteins Transporters
| | | | | Expressed in all |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
NCAPD2 | Non-SMC condensin I complex, subunit D2 | Plasma proteins
| | | | | Expressed in all |
GAPDH | Glyceraldehyde-3-phosphate dehydrogenase | Enzymes Plasma proteins
| | | | | Expressed in all |
CHD4 | Chromodomain helicase DNA binding protein 4 | Cancer-related genes Enzymes Plasma proteins
| | | | | Expressed in all |
ACRBP | Acrosin binding protein | Predicted secreted proteins
| | | | | Tissue enriched |
ZNF384 | Zinc finger protein 384 | Cancer-related genes Transcription factors
| | | | | Expressed in all |
PIANP | PILR alpha associated neural protein | Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
COPS7A | COP9 signalosome subunit 7A | | | | | | Expressed in all |
MLF2 | Myeloid leukemia factor 2 | | | | | | Expressed in all |
PTMS | Parathymosin | | | | | | Expressed in all |
LAG3 | Lymphocyte-activation gene 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CD4 | CD4 molecule | CD markers FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
GPR162 | G protein-coupled receptor 162 | G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
SPSB2 | SplA/ryanodine receptor domain and SOCS box containing 2 | | | | | | Expressed in all |
LRRC23 | Leucine rich repeat containing 23 | | | | | | Group enriched |
ENO2 | Enolase 2 (gamma, neuronal) | Cancer-related genes Candidate cardiovascular disease genes Enzymes Plasma proteins
| | | | | Expressed in all |
PTPN6 | Protein tyrosine phosphatase, non-receptor type 6 | Enzymes Plasma proteins
| | | | | Expressed in all |
EMG1 | EMG1 N1-specific pseudouridine methyltransferase | | | | | | Expressed in all |
PHB2 | Prohibitin 2 | Mitochondrial proteins Plasma proteins
| | | | | Expressed in all |
C1S | Complement component 1, s subcomponent | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Expressed in all |
RBP5 | Retinol binding protein 5, cellular | Plasma proteins
| | | | | Tissue enhanced |
PEX5 | Peroxisomal biogenesis factor 5 | Disease related genes
| | | | | Expressed in all |
CD163L1 | CD163 molecule-like 1 | CD markers Predicted membrane proteins
| | | | | Mixed |
CD163 | CD163 molecule | CD markers Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
NANOG | Nanog homeobox | Transcription factors
| | | | | Tissue enhanced |
SLC2A3 | Solute carrier family 2 (facilitated glucose transporter), member 3 | Predicted membrane proteins Transporters
| | | | | Expressed in all |
CLEC4A | C-type lectin domain family 4, member A | Predicted membrane proteins
| | | | | Tissue enhanced |
CLEC4D | C-type lectin domain family 4, member D | Predicted membrane proteins
| | | | | Group enriched |
MFAP5 | Microfibrillar associated protein 5 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
A2ML1 | Alpha-2-macroglobulin-like 1 | Predicted secreted proteins
| | | | | Tissue enriched |
PHC1 | Polyhomeotic homolog 1 (Drosophila) | Disease related genes
| | | | | Expressed in all |
A2M | Alpha-2-macroglobulin | Cancer-related genes Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
PZP | Pregnancy-zone protein | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Mixed |
CD69 | CD69 molecule | CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
CLEC2B | C-type lectin domain family 2, member B | Predicted secreted proteins
| | | | | Mixed |
CLEC12A | C-type lectin domain family 12, member A | Predicted membrane proteins
| | | | | Tissue enhanced |
KLRK1 | Killer cell lectin-like receptor subfamily K, member 1 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |